GSK3B and ovarian adenocarcinoma: Mutations of the β-catenin gene at the binding site for GSK3β was demonstrated in 16–30% of the endometrioid type of ovarian adenocarcinomas, but not in other types of ovarian tumours (Gamallo et al, 1999; Wright et al, 1999).